858 related articles for article (PubMed ID: 26922134)
1. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
Seigneurie AS; Sauvanaud F; Limosin F
Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
[TBL] [Abstract][Full Text] [Related]
2. Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis.
Carbon M; Hsieh CH; Kane JM; Correll CU
J Clin Psychiatry; 2017 Mar; 78(3):e264-e278. PubMed ID: 28146614
[TBL] [Abstract][Full Text] [Related]
3. Antipsychotic-induced Tardive dyskinesia: from biological basis to clinical management.
Salem H; Pigott T; Zhang XY; Zeni CP; Teixeira AL
Expert Rev Neurother; 2017 Sep; 17(9):883-894. PubMed ID: 28750568
[TBL] [Abstract][Full Text] [Related]
4. Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.
Niemann N; Jankovic J
Drugs; 2018 Apr; 78(5):525-541. PubMed ID: 29484607
[TBL] [Abstract][Full Text] [Related]
5. Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: the Curaçao extrapyramidal syndromes study V.
van Harten PN; Hoek HW; Matroos GE; van Os J
J Clin Psychiatry; 2006 Dec; 67(12):1920-7. PubMed ID: 17194270
[TBL] [Abstract][Full Text] [Related]
6. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 3: Clinical Trial Data.
Preskorn SH; Macaluso M
J Psychiatr Pract; 2016 Mar; 22(2):117-23. PubMed ID: 27138080
[TBL] [Abstract][Full Text] [Related]
7. Historical perspectives on tardive dyskinesia.
Caroff SN; Ungvari GS; Cunningham Owens DG
J Neurol Sci; 2018 Jun; 389():4-9. PubMed ID: 29454494
[TBL] [Abstract][Full Text] [Related]
8. [Antipsychotic-induced tardive syndromes].
Fleischhacker WW; Hofer A; Jagsch C; Pirker W; Psota G; Rittmannsberger H; Seppi K
Neuropsychiatr; 2016 Sep; 30(3):123-130. PubMed ID: 27580887
[TBL] [Abstract][Full Text] [Related]
9. Valbenazine for the treatment of tardive dyskinesia.
Seeberger LC; Hauser RA
Expert Opin Pharmacother; 2017 Aug; 18(12):1279-1287. PubMed ID: 28699794
[TBL] [Abstract][Full Text] [Related]
10. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
McGrath JJ; Soares KV
Cochrane Database Syst Rev; 2000; (2):CD000459. PubMed ID: 10796546
[TBL] [Abstract][Full Text] [Related]
11. Clinical risk factors for the development of tardive dyskinesia.
Solmi M; Pigato G; Kane JM; Correll CU
J Neurol Sci; 2018 Jun; 389():21-27. PubMed ID: 29439776
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapy for the treatment of tardive dyskinesia in schizophrenia patients.
Witter DP; Holbert RC; Suryadevara U
Expert Opin Pharmacother; 2017 Jul; 18(10):965-972. PubMed ID: 28443349
[TBL] [Abstract][Full Text] [Related]
13. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
Bret P; Bret MC; Queuille E
Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
[TBL] [Abstract][Full Text] [Related]
14. Focus on lower risk of tardive dyskinesia with atypical antipsychotics.
Nasrallah HA
Ann Clin Psychiatry; 2006; 18(1):57-62. PubMed ID: 16517454
[TBL] [Abstract][Full Text] [Related]
15. Tardive drug-induced extrapyramidal syndromes.
Marsálek M
Pharmacopsychiatry; 2000 Sep; 33 Suppl 1():14-33. PubMed ID: 11072762
[TBL] [Abstract][Full Text] [Related]
16. Effect of Antipsychotic Type and Dose Changes on Tardive Dyskinesia and Parkinsonism Severity in Patients With a Serious Mental Illness: The Curaçao Extrapyramidal Syndromes Study XII.
Mentzel CL; Bakker PR; van Os J; Drukker M; Matroos GE; Hoek HW; Tijssen MA; van Harten PN
J Clin Psychiatry; 2017 Mar; 78(3):e279-e285. PubMed ID: 28199071
[TBL] [Abstract][Full Text] [Related]
17. Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 4: Case Report Data.
Macaluso M; Flynn A; Preskorn S
J Psychiatr Pract; 2016 May; 22(3):203-20. PubMed ID: 27123800
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology, Prevention, and Assessment of Tardive Dyskinesia and Advances in Treatment.
Correll CU; Kane JM; Citrome LL
J Clin Psychiatry; 2017; 78(8):1136-1147. PubMed ID: 29022654
[TBL] [Abstract][Full Text] [Related]
19. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
[TBL] [Abstract][Full Text] [Related]
20. Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies.
Stegmayer K; Walther S; van Harten P
CNS Drugs; 2018 Feb; 32(2):135-147. PubMed ID: 29427000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
